Regulus Therapeutics (RGLS) Tops Q4 EPS by 2c

Regulus Therapeutics (NASDAQ: RGLS) reported Q4 EPS of ($0.14), $0.02 better than the analyst estimate of ($0.16).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Turning Point Brands (TPB) PT Lowered to $90 at Oppenheimer
• Bernstein SocGen Group Upgrades Engie SA (ENGI:FP) (ENGIY) to Outperform